4 UAE checks before hysterectomy for cancer suspicion or fibroids

A woman in the UAE usually needs her uterus removed when cancer is confirmed or strongly suspected, or when fibroids cause severe bleeding, pain, pressure or fertility failure after lower-risk options have been assessed.

That is the clinical question raised by a Gulf News report on hysterectomy decisions in the UAE, and it matters beyond the consultation room. For Dubai clinics, Abu Dhabi hospitals and northern emirates providers, the issue is triage: who needs a gynaecologic oncology referral, who can be managed with uterus-preserving treatment, and what insurers will authorise before surgery.

What should trigger escalation

The first split is cancer risk. Post-menopausal bleeding, abnormal cervical screening, suspicious ultrasound findings or rapid uterine enlargement should push the case into a cancer pathway. In Dubai, oncology service governance sits with the Dubai Health Authority (DHA), which announced updated oncology service standards on 25 June 2024 in collaboration with the Emirates Oncology Society. Operators should treat those standards as the baseline for referral protocols, credentialing and multidisciplinary review.

Fibroids usually follow a different pathway. They are benign uterine growths, but they can still cause heavy menstrual bleeding, anaemia, pelvic pressure, urinary symptoms and infertility. Uterus-preserving options can include medication, hysteroscopic resection, laparoscopic or open myomectomy, uterine artery embolisation and focused ultrasound where available. Hysterectomy is definitive because it removes the uterus. It also ends fertility, which changes the consent standard for women who may want pregnancy.

• Red flags: post-menopausal bleeding, suspicious imaging, abnormal biopsy, unexplained weight loss or suspected cervical, endometrial or ovarian cancer.
• Fibroid indications: heavy bleeding with anaemia, pressure symptoms, recurrent pain, failed medical therapy or fertility impact after specialist assessment.
• Uterus-sparing review: document whether myomectomy, embolisation or hysteroscopic treatment is clinically suitable before elective hysterectomy.
• Insurance file: attach ultrasound or MRI findings, haemoglobin results, biopsy reports where relevant and prior treatment history.

What clinics and insurers need to document

For COOs, the operational risk is a weak referral and consent pathway. A general obstetrics and gynaecology clinic can diagnose symptoms and order imaging. Suspected malignancy should move to a licensed oncology or gynaecologic oncology service. In Abu Dhabi, the Department of Health Abu Dhabi (DOH) Oncology and Hematology Services Jawda Guidance applies to DOH-licensed hospitals providing inpatient and medical day-case oncology services, and requires nominated facility leads to submit quarterly quality indicators through the DOH online portal.

For CFOs, the price question is less useful than the authorisation question. Published UAE cash-pay hysterectomy estimates are uneven. One international treatment marketplace lists UAE hysterectomy prices at $9,800 to $18,200, about AED 36,000 to AED 66,800, but that is a broker benchmark rather than a payer tariff. UAE operators should pull the relevant DRG, CPT or package rate from contracts with Daman, Thiqa or Sukoon, then check whether the case needs pre-authorisation, second opinion approval, inpatient admission approval or oncology board documentation.

Patients also need a clearer financial pathway. A woman comparing fibroid treatments may face different out-of-pocket exposure for outpatient medication, day-case embolisation and inpatient surgery. The clinic should give the patient a written estimate because fibroid number, uterine size, surgical route, inpatient days and pathology testing all change the bill.

Why the UAE market should care

The business implication is service-line design. Dubai providers need a pathway that can separate suspected cancer from benign fibroid disease at the first or second visit. Abu Dhabi providers need the same pathway with DOH quality reporting built in. In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah, providers should map referral routes against Ministry of Health and Prevention (MOHAP) licensed facilities and professionals.

Medical directors should audit elective hysterectomy files for four items: documented indication, completed imaging, fertility and menopause counselling, and evidence that uterus-preserving treatment was considered where clinically appropriate. CIOs should make those fields mandatory in the electronic medical record. Insurers should require the same data before approval, since incomplete files create delays and increase dispute risk after admission.

The next pressure point is patient acquisition. Women are searching for second opinions on fibroids because uterus removal is irreversible. Clinics that can publish a responsible pathway, list available uterus-sparing procedures and show the licence status of their doctors will be easier to trust than clinics selling one procedure first.

Patients and operators checking oncology capacity should start with the UAE Open Healthcare Directory, which lists licensed healthcare providers across all seven emirates and includes oncology and cancer care filters. Dubai users can cross-check licences through the DHA Dubai Medical Registry, Abu Dhabi users can search DOH facilities through TAMM, and northern emirates users can use the MOHAP medical facilities directory.